Abstract:Background: Principally 80 percent of the malignant oral tumors are the Oral Squamous Cell Carcinoma (OSCC), which require quantities of such sacrifices as deformity, malfunction, recurrence, metastasis, deterioration, and mortality in common cases of failing to antedate diagnosis. Similarly critical is the Oral Leukoplakia (OLK) among precancerous lesions of oral mucosa. It would also be of interest for scholars and clinicians to target the discrimination as seizing up OLK intimate to OSCC. Objective: Through bioinformatics technology, the research in narration worked to establish a three-dimensional discriminate database from high throughput data of protein fingerprints from serum, saliva, and tissue samples of OSCC and OLK patients as a preliminary step towards integrated group proteins biomarker discovery and to further understanding of corresponding tumorgenesis and proteomics. Methods: Differential proteomic patterns in serum, saliva, and tissue between OSCC patients or OSCC tissues and OLK were detected by SELDI-TOF-MS technology, and discriminatively analyzed by ZUCI-PDAS (Zhejiang University Cancer Institute ProteinChip Data Analysis System) with Support Vector Machines (SVM) and cross validation. Additionally, Laser Capture Micro-dissection technology was utilized in the tissue research. Results: Mass/charge proteomes of optimization obtained from the samples were, respectively, 4162 with 6886 of 87.82%, 92.86%, 66.67% as the sensitivity, specificity, and accuracy for serum difference; m/z 5818, 4617 with 3884 of all 100% as the sensitivity, specificity, and accuracy for saliva difference; and m/z 3738, 11366 of 96.29%, 100.00%, 85.71% as the sensitivity, specificity, and accuracy for tissue difference between OSCC and OLK patients. Conclusions: Within the fields of clinical biomarker application and bioinformatics utilization, as well as the exploitation and popularization of modern discriminate analysis technology, to determine preventative and therapeutic stage and prognosis of OSCC and OLK, the proteomes of optimization for discrepancy are suggested to be directly enrolled in clinical application without protein identification.

Oncoproteomics: Trials and Tribulations

Oncoproteomics: current trends and future perspectives

A new and preliminary three-dimensional perspective: proteomes of optimization between OSCC and OLK.

Proteomics, Personalized Medicine and Cancer

Advances in the Application of Proteomics in Lung Cancer

Proteomic Approaches to Tumor Biomarkers: the Strategy, Challenge and Outlook

Proteasome dysregulation in human cancer: implications for clinical therapies

Proteomic and genomic profiling of pancreatic cancer

Omics‐Enhanced Nanomedicine for Cancer Therapy

Proteomics‐based interrogation of the kinome and its implications for precision oncology

Genomic and oncoproteomic advances in detection and treatment of colorectal cancer

Proteomics approaches to characterize the immune responses in cancer

Proteomics to study cancer immunity and improve treatment

Proteomics in human cancer research

Realm of proteomics in breast cancer management and drug repurposing to alleviate intricacies of treatment

Proteomics for cancer drug design

Proteomic landscape of epithelial ovarian cancer

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era

Advances in the Clinical Application of High-throughput Proteomics

OncoCTMiner: streamlining precision oncology trial matching via molecular profile analysis

Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era